FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963708576> ?p ?o ?g. }

• W1963708576 endingPage "53" @default.
• W1963708576 startingPage "49" @default.
• W1963708576 abstract "Background and objective: Invasive pulmonary aspergillosis (IPA) is a serious cause of death among immune-compromised patients such as organ-transplant recipients. Recently, voriconazole has been approved for first-line therapy in IPA. Theoretically, optimal voriconazole blood level (superior to 1 mg/L according to recent studies) should be reached within 24 h. In practice, a significantly longer time seems to be needed in lung-transplant recipients. Therefore, caspofungin is now used in combination with voriconazole to provide cover against Aspergillus spp. infection during this gap. The first aim of this study was to investigate Aspergillus spp. infection treated with this combination and the atter’s tolerability. The median time for attainment of apparently active blood levels in lung transplant recipients were compared between those with cystic fibrosis and those without. Methods: Lung-transplant recipients who received a combination of voriconazole and caspofungin between 2002 and 2008 as primary therapy were identified retrospectively. The median number of days to reach active voriconazole blood levels was compared between cystic fibrosis and other patients by Student’s t-test. Statistical significance was defined by P-value <0·05. Results: Four patients were treated for Aspergillus colonization before transplantation and their culture were negative at 90 days. Eleven patients were treated for proven or probable invasive aspergillosis and 14 of them had a complete response. Hallucinations (n = 2) and significant hepatic toxicity (n = 2) were reported. Among the 15 studied transplant recipients, a median of 12·3 days was observed for active voriconazole blood levels to be reached. With cystic fibrosis patients, time tended to be longer than with other recipients (14·9 days vs. 8·3 days). Tacrolimus blood levels (between 5 and 15 ng/mL) may have been increased by voriconazole. Conclusion: This retrospective study describes practical experience in the management of this rare and severe disease in a referral centre for cystic fibrosis lung transplantation. Voriconazole and caspofungin combination was acceptably safe and was associated with good clinical outcomes in almost all patients. We showed that in 15 lung-transplant recipients a median of 12·3 days was required for voriconazole to reach high enough blood levels. Caspofungin in combination with voriconazole provides cover against Aspergillus infection during the period when voriconazole may be at subtherapeutic levels with good tolerability." @default.
• W1963708576 created "2016-06-24" @default.
• W1963708576 creator A5002049351 @default.
• W1963708576 creator A5028383929 @default.
• W1963708576 creator A5045032085 @default.
• W1963708576 creator A5050461112 @default.
• W1963708576 creator A5054026459 @default.
• W1963708576 creator A5054848085 @default.
• W1963708576 creator A5056021009 @default.
• W1963708576 creator A5083199308 @default.
• W1963708576 creator A5086391184 @default.
• W1963708576 date "2010-02-01" @default.
• W1963708576 modified "2023-09-30" @default.
• W1963708576 title "Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis" @default.
• W1963708576 cites W1583606950 @default.
• W1963708576 cites W1994312167 @default.
• W1963708576 cites W2009988670 @default.
• W1963708576 cites W2038878095 @default.
• W1963708576 cites W2082695689 @default.
• W1963708576 cites W2090225402 @default.
• W1963708576 cites W2095276293 @default.
• W1963708576 cites W2099140379 @default.
• W1963708576 cites W2099769947 @default.
• W1963708576 cites W2100346956 @default.
• W1963708576 cites W2116088133 @default.
• W1963708576 cites W2123134253 @default.
• W1963708576 cites W2133328722 @default.
• W1963708576 cites W2162857158 @default.
• W1963708576 cites W3025952528 @default.
• W1963708576 doi "https://doi.org/10.1111/j.1365-2710.2009.01061.x" @default.
• W1963708576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20175811" @default.
• W1963708576 hasPublicationYear "2010" @default.
• W1963708576 type Work @default.
• W1963708576 sameAs 1963708576 @default.
• W1963708576 citedByCount "21" @default.
• W1963708576 countsByYear W19637085762012 @default.
• W1963708576 countsByYear W19637085762013 @default.
• W1963708576 countsByYear W19637085762014 @default.
• W1963708576 countsByYear W19637085762015 @default.
• W1963708576 countsByYear W19637085762016 @default.
• W1963708576 countsByYear W19637085762017 @default.
• W1963708576 countsByYear W19637085762019 @default.
• W1963708576 countsByYear W19637085762022 @default.
• W1963708576 crossrefType "journal-article" @default.
• W1963708576 hasAuthorship W1963708576A5002049351 @default.
• W1963708576 hasAuthorship W1963708576A5028383929 @default.
• W1963708576 hasAuthorship W1963708576A5045032085 @default.
• W1963708576 hasAuthorship W1963708576A5050461112 @default.
• W1963708576 hasAuthorship W1963708576A5054026459 @default.
• W1963708576 hasAuthorship W1963708576A5054848085 @default.
• W1963708576 hasAuthorship W1963708576A5056021009 @default.
• W1963708576 hasAuthorship W1963708576A5083199308 @default.
• W1963708576 hasAuthorship W1963708576A5086391184 @default.
• W1963708576 hasBestOaLocation W19637085761 @default.
• W1963708576 hasConcept C126322002 @default.
• W1963708576 hasConcept C141071460 @default.
• W1963708576 hasConcept C16005928 @default.
• W1963708576 hasConcept C197934379 @default.
• W1963708576 hasConcept C203014093 @default.
• W1963708576 hasConcept C2776391196 @default.
• W1963708576 hasConcept C2776938444 @default.
• W1963708576 hasConcept C2777714996 @default.
• W1963708576 hasConcept C2778375690 @default.
• W1963708576 hasConcept C2779548794 @default.
• W1963708576 hasConcept C2780402444 @default.
• W1963708576 hasConcept C2780690907 @default.
• W1963708576 hasConcept C2781448352 @default.
• W1963708576 hasConcept C2911091166 @default.
• W1963708576 hasConcept C71924100 @default.
• W1963708576 hasConcept C90924648 @default.
• W1963708576 hasConceptScore W1963708576C126322002 @default.
• W1963708576 hasConceptScore W1963708576C141071460 @default.
• W1963708576 hasConceptScore W1963708576C16005928 @default.
• W1963708576 hasConceptScore W1963708576C197934379 @default.
• W1963708576 hasConceptScore W1963708576C203014093 @default.
• W1963708576 hasConceptScore W1963708576C2776391196 @default.
• W1963708576 hasConceptScore W1963708576C2776938444 @default.
• W1963708576 hasConceptScore W1963708576C2777714996 @default.
• W1963708576 hasConceptScore W1963708576C2778375690 @default.
• W1963708576 hasConceptScore W1963708576C2779548794 @default.
• W1963708576 hasConceptScore W1963708576C2780402444 @default.
• W1963708576 hasConceptScore W1963708576C2780690907 @default.
• W1963708576 hasConceptScore W1963708576C2781448352 @default.
• W1963708576 hasConceptScore W1963708576C2911091166 @default.
• W1963708576 hasConceptScore W1963708576C71924100 @default.
• W1963708576 hasConceptScore W1963708576C90924648 @default.
• W1963708576 hasIssue "1" @default.
• W1963708576 hasLocation W19637085761 @default.
• W1963708576 hasLocation W19637085762 @default.
• W1963708576 hasOpenAccess W1963708576 @default.
• W1963708576 hasPrimaryLocation W19637085761 @default.
• W1963708576 hasRelatedWork W1968772793 @default.
• W1963708576 hasRelatedWork W1989263970 @default.
• W1963708576 hasRelatedWork W1994312167 @default.
• W1963708576 hasRelatedWork W2049181212 @default.
• W1963708576 hasRelatedWork W2059743756 @default.
• W1963708576 hasRelatedWork W2082037991 @default.
• W1963708576 hasRelatedWork W2096795316 @default.

• next